Advanced Practice Rheum: Steroids Save

Know-it-Now

• Corticosteroids (CS) are rapidly effective but chronically dangerous
• High-dose regimens should be reserved for life-threatening conditions
• Even low doses (e.g., < 4 mg/day) are associated with significantly increased rates of serious infection, and cardiovascular complications
• All steroid prescriptions should carry an explicit expiration date

In this Advanced Practice Rheum, Dr. Jack Cush reviews steroids (slide deck available). Corticosteroids remain a cornerstone of rheumatologic therapy — rapidly effective but chronically dangerous, as their power to suppress inflammation through inhibition of prostaglandins, lipoxygenase, pro-inflammatory cytokines, and proteases comes at the cost of a broad and serious adverse effect profile. Dosing ranges from low (≤5 mg/day prednisone) to high (≥1 mg/kg/day) and pulse IV methylprednisolone (1 g/day × 3 days), with high-dose regimens reserved for life-threatening conditions such as systemic necrotizing vasculitis, lupus nephritis, neuropsychiatric lupus, and idiopathic inflammatory myositis. Even doses as low as 4 mg/day of prednisone have been associated with significantly increased rates of serious infection, atrial fibrillation, and heart failure, underscoring that risk stratification by both patient disease activity and comorbidity burden is essential before prescribing. Clinicians should provide patients with full disclosure of adverse effects — including metabolic, cardiovascular, ophthalmologic, musculoskeletal, infectious, and neuropsychiatric risks — and every steroid prescription should carry an explicit expiration date, with tapering guided by both disease activity and the distinction between true disease flare and steroid withdrawal syndrome, the latter presenting with fatigue, arthralgias, myalgias, and mood changes that can mimic underlying disease recurrence. Surgical patients on chronic steroids should continue their maintenance dose perioperatively, as stress dosing has not been shown to be necessary. Ultimately, steroids should function as a bridge to steroid-sparing disease-modifying therapy, with a goal of discontinuation within 8–12 weeks whenever clinically feasible.

Check out the complete Advanced Practice Rheum video series, featuring these topics: methotrexate; difficult-to-treat rheumatoid arthritis; antinuclear antibodies (ANA); evaluation of rheumatic complaints; rheumatoid & inflammation testing; and more.